Legend Capital

Legend Capital is a Beijing-based venture capital firm and subsidiary of Legend Holdings. Founded in 2001, it focuses on early-stage and growth investments in technology-driven sectors with operations anchored in China and related markets. The firm backs companies in IT, internet applications and services, outsourcing, IC design and key components, as well as sectors such as telecommunications, media, healthcare, consumer and intelligent manufacturing. It manages multiple funds and actively supports portfolio companies with business development, market positioning and access to Chinese markets to create value. Legend Capital aims to back high-growth ventures and build lasting value in China's venture capital ecosystem.

Daqing Cai

Managing Director

Chen Hao

Managing Director and Head of Investment

Rui Chen

Managing Director

Raymond Chen

Co-Chief Investment Officer

FAN Qihui

Executive Director

Past deals in Series D

Core Medical Technology

Series D in 2025
Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

TBSTest Technology

Series D in 2024
TBSTest Technology is a developer and manufacturer of semiconductor test equipment, focusing on integrated circuit automatic test equipment, ATE, and SOC test equipment. It provides testing solutions including hardware, software, test boards, and memory systems, and offers pre-sales and after-sales support. The company serves IC designers and producers as well as scientific research institutions and universities. Founded in 2017, it is based in Beijing with branch offices in Xi’an, Shanghai, and Suwon, South Korea.

Zhipu AI

Series D in 2024
Zhipu AI is a technology company specializing in developing large-scale artificial intelligence models. It offers API services powered by its General Language Model (GLM) series, designed to handle both Chinese and English tasks. The company's products include chatbots and advanced AI tools, aiming to reduce manual labor in digital tasks.

MS Energy

Series D in 2024
MS Energy is a technology-driven enterprise that specializes in green energy solutions and advanced lithium battery energy storage technologies. The company develops lithium battery energy storage safety systems and a digital platform designed to accelerate the global energy internet, including a pre-diagnosis management platform that provides safety warnings and battery management capabilities. It serves industrial users with integrated green energy services, combining safety, monitoring, and efficiency to support scalable and reliable energy storage and utilization.

Leadrive

Series D in 2023
LEADRIVE is a technology company specializing in the research, development, production, and sales of drive solutions for new energy vehicles, as well as high-performance power semiconductor modules. The company designs and manufactures advanced motor controllers and proprietary power modules that have been adopted by over ten leading automotive manufacturers and Tier-1 suppliers for mass production. LEADRIVE is also engaged in enhancing the localization of power semiconductor modules, with ongoing certification processes for silicon carbide modules and electronic controls. Additionally, the company invests in innovative energy solutions, including wind, solar, and energy storage systems. In collaboration with Rohm Semiconductor from Japan, LEADRIVE has established a joint laboratory to develop various silicon carbide modules, focusing on improving efficiency through comprehensive simulation, testing, and development processes that span from device-level to vehicle-level applications.

Ligatech Bioscience

Series D in 2023
Ligatech Bioscience, established in 2014 and headquartered in Qingpu, China, specializes in the design, development, production, and sales of medical devices for orthopedic and sports medicine. Its product portfolio includes molecular weight polyethylene suture and striped titanium plates, along with artificial ligaments and fixation systems. The company also offers technical advice and services to its users.

GalaxySpace

Series D in 2022
Founded in 2016, GalaxySpace specializes in developing and manufacturing low Earth orbit (LEO) broadband satellite constellations for global internet connectivity. Their satellite applications include monitoring services for airports, parking lots, oil reserves, and land use assessment.

TOPNC

Series D in 2022
TOPNC specializes in CNC technology, precision transmission and advanced process technology, producing CNC machine tools and other major manufacturing equipment used in high-end manufacturing and pursuing innovation in domestic CNC equipment. The company designs, develops, manufactures, and sells high-end intelligent manufacturing equipment, including five-axis CNC machine tools, with a focus on aerospace applications to meet the advanced manufacturing needs of China's aerospace industry.

Fit2Cloud

Series D in 2022
Fit2Cloud, established in 2014, is a prominent provider of Multi-Cloud Management Platform solutions in China. The company focuses on enhancing the cloud management experience for enterprise customers across various multi-cloud environments. Fit2Cloud's offerings address critical issues related to IT operation security and continuous application delivery. Their product lineup includes a comprehensive Cloud Management Platform, JumpServer (an open-source fortress machine), DataEase (an open-source data visualization and analysis platform), and MeterSphere (an open-source continuous testing platform). Through these solutions, Fit2Cloud empowers enterprises to effectively manage and utilize cloud services, facilitating their digital transformation and ensuring a seamless operational experience.

Haizhi Wangju Internet Technology

Series D in 2022
BDP (Business Data Platform) by a sea of production. Sea of ​​co-founded by former Baidu founding team members and executives, core team members from Baidu, Microsoft, IBM, EMC, Silicon Valley veteran Internet and IT experts, has received a number of top venture capital co-investment fund.

Hong Kong Asia Heart Centre

Series D in 2022
Hong Kong Asia Heart Centre is a cardiovascular specialist chain that provides various cardiovascular assessment and surgical services. Founded in 1999, The Hong Kong Asian Heart Center has a professional medical team with many years of experience in the treatment of heart disease.

Wangdiantong

Series D in 2021
Wangdiantong is a provider of enterprise-level e-commerce solutions, specializing in retail cloud services that facilitate the digital transformation of businesses. The company offers a comprehensive ERP system that integrates with major online platforms such as Taobao, Tmall, and Amazon, among others. Its solutions encompass a wide range of functionalities, including inventory management, order processing, purchasing, after-sales support, accounts management, and customer relationship management (CRM). Additionally, Wangdiantong supports multi-warehouse operations and provides tools for managing both online and physical store cashiers. By leveraging intelligent warehouse and ERP solutions, the company aims to help businesses scale and achieve efficient, intelligent management practices in an increasingly digital marketplace.

JenaValve Technology

Series D in 2020
JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Bondent

Series D in 2019
Bondent Technology Co., Ltd., headquartered in Shanghai, China, specializes in supplying dental equipment and materials. It offers a comprehensive range of services, including technical training, operational and management consulting, decoration design, and financial solutions. Bondent's core business involves the design, development, manufacturing, and sales of oral medical equipment, creating a full ecosystem for the dental and oral health industry.

Zhenkunxing

Series D in 2019
ZKH is a digital service platform for industrial products that offers comprehensive supply chain solutions based on an E-commerce platform, digital tools, and intelligent service. Its platform offers a comprehensive selection of industrial accessories, consumables, general equipment, and spare parts. There are 28 product lines and over 4 million SKUs available, including PPE, hand tools, metal processing, fasteners, instruments, chemicals, and so on.

AoHua

Series D in 2018
Aohua is a global provider of endoscopy devices and solutions, focused on advancing endoscope technology and enhancing diagnostic and treatment capabilities in endoscopy. Founded in 1994 and based in Shanghai, China, the company specializes in the research, development, production, and sales of electronic endoscope equipment, along with associated diagnostic and surgical consumables. Aohua aims to lead innovation in endoscopic technology, contributing to the overall progress of medical endoscopy practices.

Alo7

Series D in 2017
ALO7 is the largest digital English Language Teaching (ELT) product and solutions provider in China, boasting over 10 million registered users and more than 2,000 training school partners. The company operates an online tutoring platform designed to support young Chinese students in learning English. By leveraging technology, ALO7 facilitates interactions among students, teachers, parents, and school administrators, thereby enhancing both online and offline educational experiences. The platform offers fun and interactive classes that blend education with play, ensuring high-quality teaching products and services are accessible to schools and learners alike. Through its innovative approach, ALO7 is transforming the landscape of English language education in China.

Innovent Biologics

Series D in 2016
Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.

PegBio

Series D in 2016
PegBio is a biopharmaceutical company based in Suzhou, focused on polyethylene glycol (PEG) chemistry and PEGylation technology to develop and manufacture PEGylated drugs as potential new molecule entities. The company offers PEG synthesis and PEGylation services, including N-terminal specific, thiol-selective, and enzymatic PEGylation, along with pharmaceutical-grade PEGs and activated PEGs for research and pharmaceutical applications. It provides PEGylation services to universities, research institutes, and pharmaceutical companies and develops PEGylated peptides and antibody fragments for therapeutic areas such as type II diabetes and rheumatoid arthritis. PegBio also develops PB-119, a glucagon-like peptide-1 (GLP-1) receptor agonist designed for less frequent dosing, and engages in collaborations with strategic partners to modify macromolecules and advance PEGylated biopharmaceuticals.

Bionano Genomics

Series D in 2016
Bionano Genomics, Inc. is a biotechnology company focused on genome mapping and analysis. It develops and markets the Saphyr system, an advanced platform designed for ultra-sensitive and specific detection of structural variations in DNA, such as insertions, deletions, and translocations, which are often linked to genetic disorders and diseases, including cancer. The Saphyr system employs optical genome mapping technology, allowing for direct visualization and analysis of long DNA molecules without relying on sequencing. This capability provides researchers and clinicians with critical insights into the structural variations within genomes, enhancing the understanding of disease mechanisms and supporting the development of personalized treatment strategies. Bionano Genomics also offers essential reagents and data solutions, including Bionano prep kits, labeling kits, and software tools for comprehensive experiment management. Its products are primarily sold to academic and governmental research laboratories, as well as pharmaceutical, biotechnology, and contract research organizations across multiple regions, including North America, Europe, and Asia. Founded in 2003 and headquartered in San Diego, California, the company was previously known as BioNano Genomics, Inc. until its name change in July 2018.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.